Early Use of the NMDA Receptor Antagonist Ketamine in Refractory and Superrefractory Status Epilepticus

Refractory status epilepticus (RSE) and superrefractory status epilepticus (SRSE) pose a difficult clinical challenge. Multiple cerebral receptor and transporter changes occur with prolonged status epilepticus leading to pharmacoresistance patterns unfavorable for conventional antiepileptics. In par...

Full description

Saved in:
Bibliographic Details
Main Author: F. A. Zeiler
Format: Article
Language:English
Published: Wiley 2015-01-01
Series:Critical Care Research and Practice
Online Access:http://dx.doi.org/10.1155/2015/831260
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832545297462460416
author F. A. Zeiler
author_facet F. A. Zeiler
author_sort F. A. Zeiler
collection DOAJ
description Refractory status epilepticus (RSE) and superrefractory status epilepticus (SRSE) pose a difficult clinical challenge. Multiple cerebral receptor and transporter changes occur with prolonged status epilepticus leading to pharmacoresistance patterns unfavorable for conventional antiepileptics. In particular, n-methyl-d-aspartate (NMDA) receptor upregulation leads to glutamate mediated excitotoxicity. Targeting these NMDA receptors may provide a novel approach to otherwise refractory seizures. Ketamine has been utilized in RSE. Recent systematic review indicates 56.5% and 63.5% cessation in seizures in adults and pediatrics, respectively. No complications were described. We should consider earlier implementation of ketamine or other NMDA receptor antagonists, for RSE. Prospective study of early implementation of ketamine should shed light on the role of such medications in RSE.
format Article
id doaj-art-4175f95bdbaf4c26ab53d2d4ee49efca
institution Kabale University
issn 2090-1305
2090-1313
language English
publishDate 2015-01-01
publisher Wiley
record_format Article
series Critical Care Research and Practice
spelling doaj-art-4175f95bdbaf4c26ab53d2d4ee49efca2025-02-03T07:26:12ZengWileyCritical Care Research and Practice2090-13052090-13132015-01-01201510.1155/2015/831260831260Early Use of the NMDA Receptor Antagonist Ketamine in Refractory and Superrefractory Status EpilepticusF. A. Zeiler0Section of Neurosurgery, Department of Surgery, University of Manitoba, Winnipeg, MB, R3A 1R9, CanadaRefractory status epilepticus (RSE) and superrefractory status epilepticus (SRSE) pose a difficult clinical challenge. Multiple cerebral receptor and transporter changes occur with prolonged status epilepticus leading to pharmacoresistance patterns unfavorable for conventional antiepileptics. In particular, n-methyl-d-aspartate (NMDA) receptor upregulation leads to glutamate mediated excitotoxicity. Targeting these NMDA receptors may provide a novel approach to otherwise refractory seizures. Ketamine has been utilized in RSE. Recent systematic review indicates 56.5% and 63.5% cessation in seizures in adults and pediatrics, respectively. No complications were described. We should consider earlier implementation of ketamine or other NMDA receptor antagonists, for RSE. Prospective study of early implementation of ketamine should shed light on the role of such medications in RSE.http://dx.doi.org/10.1155/2015/831260
spellingShingle F. A. Zeiler
Early Use of the NMDA Receptor Antagonist Ketamine in Refractory and Superrefractory Status Epilepticus
Critical Care Research and Practice
title Early Use of the NMDA Receptor Antagonist Ketamine in Refractory and Superrefractory Status Epilepticus
title_full Early Use of the NMDA Receptor Antagonist Ketamine in Refractory and Superrefractory Status Epilepticus
title_fullStr Early Use of the NMDA Receptor Antagonist Ketamine in Refractory and Superrefractory Status Epilepticus
title_full_unstemmed Early Use of the NMDA Receptor Antagonist Ketamine in Refractory and Superrefractory Status Epilepticus
title_short Early Use of the NMDA Receptor Antagonist Ketamine in Refractory and Superrefractory Status Epilepticus
title_sort early use of the nmda receptor antagonist ketamine in refractory and superrefractory status epilepticus
url http://dx.doi.org/10.1155/2015/831260
work_keys_str_mv AT fazeiler earlyuseofthenmdareceptorantagonistketamineinrefractoryandsuperrefractorystatusepilepticus